Citation

C Delille, I Otofokun, EP Acosta, KB Larson, K Wang. Pharmacokinetic Enhancers in HIV Therapeutics. Clinical Pharmacokinetics. 2014. 53: 865-872. PMID: 25164142

Citation

Edward P Acosta, Hedy Teppler, Brenda Homony, Bobbie Graham, Terence Fenton, Xia Xu, Larissa Wenning, Stephen A Spector, Lisa M Frenkel, Carmelita Alvero, Carol Worrell, Edward Handelsman, Andrew Winzia, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team, Sharon Nachman, Nan Zheng. Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1–Infected Children Aged 2 Through 18 Years. Clinical Infectious Diseases. 2014. 58: 413-422. PMID: 24145879

Citation

Avy Violari, Paul Palumbo, Susan H Eshleman, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1060 Study Team, Elaine J Abrams, Mutsa Bwakura-Dangarembizi, Linda Barlow-Mosha, Portia Kamthunzi, Pauline M Sambo, Mark F Cotton, Harry Moultrie, Sandhya Khadse, Werner Schimana, Raziya Bobat, Bonnie Zimmer, Elizabeth Petzold, Jane C Lindsey, Lynne M Mofenson, Michael D Hughes, Patrick Jean-Philippe. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediaric Infectious Disease Journal. 2014. 33: 846-854. PMID: 25222305

Citation

Nigel J Klein, Joanna Lewis, Ann J Melvin, Gareth Tudor-Williams, Ross E McKinney Jr, PENPACT-1 (PENTA 9/PACTG 390) Study Team, Dwight E Yin, Meredith G Warshaw, William C Miller, Hannah Castro, Susan A Fiscus, Lynda M Harper, Linda J Harrison. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. 2014. PMID: 25266426

Citation

Discordant associations between SLCO1B1 521T¿C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Therapeutic Drug Monitoring. 2013. 35: 209-216. PMID: 23503447

Citation

Participation and retention of youth with perinatal HIV infection in mental health research studies: the IMPAACT P1055 Psychiatric Comorbidity Study. Journal of Acquired Immune Deficiency Syndromes. 2013. 63: 401-9. PMID: 23714737

Citation

Raltegravir In Vitro Effect on Bilirubin Binding. Pediaric Infectious Disease Journal. 2013. 32: 978-980. PMID: 23470680

Citation

S Nachman, M Van der Linde, E Pillay, S Dittmer, S Kim, P Jean-Philippe, J Coetzee, R Bobat, E Hawkins, A Violari, P1041 Team, CA Beneri, B Zeldow. Loss to follow-up among infants in a study of isoniazid prophylaxis (P1041) in South Africa. International Journal of Tuberculosis and Lung Disease. 2013. 17: 32-38. PMID: 23232002

Citation

Social Ecological Predictors of Longitudinal Pediatric HIV Treatment Adherence. Journal of Pediatric Psychology. 2013. 38: 664-74. PMID: 23629146

Citation

PM Flynn, P Muresan, T Fenton, CK Cunningham, W Borkowsky, JB McAuley, SA Spector, E Petzold, W Levy, GK Siberry, E Handelsman, LJ Utech, A Weinberg, RF Pass, S Nachman. Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth. 2013. 2: 352-360. PMID: 24363932